Certified by Founder
Lodge
HI-Bio
start up
United States
- South San Francisco, California
- 05/01/2024
- Series B
- $95,000,000
Human Immunology Biosciences (HI-Bio) is leading clinical immunology into its next chapter with therapies that target cellular drivers of disease. HI-Bio uses a precision medicine approach to deliver therapies for patients with the auto-immune, allergic and inflammatory diseases that can together be referred to as immune-mediated diseases (IMDs).
- Industry Biotechnology Research
- Website https://hibio.com/
- LinkedIn https://www.linkedin.com/company/hibio/about/
Vor Systems | $3,000,000 | (Mar 6, 2026)
IntelliGRC | $3,500,000 | (Mar 6, 2026)
Cyclops | $8,000,000 | (Mar 6, 2026)
Lio (formerly askLio) | $30,000,000 | (Mar 6, 2026)
Navigara | $2,500,000 | (Mar 6, 2026)
AgriPass | $7,500,000 | (Mar 6, 2026)
Reclaim Security | $20,000,000 | (Mar 6, 2026)
NextWork | $4,450,000 | (Mar 6, 2026)
Vast | $500,000,000 | (Mar 6, 2026)
Qura | $1,739,595 | (Mar 4, 2026)
Escargot | $2,750,000 | (Mar 4, 2026)
Worldscape | Undisclosed Amount | (Mar 4, 2026)